| HOME | ABOUT |
MISSION STATEMENT
Celiac disease (CD) is a chronic intestinal disorder affecting as much as 0.3-1.0% of the population. However, about 85% of patients are not properly diagnosed. If recognised, patients have only limited access to safe foods and there is no causal therapy available. By incorporating leaders from academia, patient organisations, and industry, the Coeliac Disease Consortium (CDC) will form a network to generate the scientific basis for innovative improvements to the quality of life of CD patients.
It’s the CDC’s mission to develop the scientific bases for safer foods and for effective diagnosis, prevention, and therapy of CD. Building on recent progress in CD research, we will use functional genomics to elucidate the potentially fatal interaction between the disease-inducing dietary proteins and the human host at the molecular level.
The goals of the CDC are the development of improved diagnostic procedures, novel therapeutics and safer foods for celiac disease patients. The results of these studies will be presented on scientific meetings and published in peer reviewed scientific journals. It is expected to lead to several PhD theses. Where necessary, patent applications will be filed in order to protect novel findings and insights that have potential for commercialization. Throughout the project there is a close contact with the Dutch Coeliac Disease Society, one of the stakeholders in the consortium, to keep them updated on the progress and its impact. Moreover, throughout the project we will seek contact with relevant industrial partners, medical and patient organizations, health insurance companies and policy makers.